"Results from this phase II trial demonstrate a significant reduction in respiratory adverse events such as COPD exacerbations and hospitalizations of greater than 50 percent. I believe these results may have important implications for COPD sufferers and their overall quality of life, as well as for healthcare costs, as there is significant expense associated with exacerbations and hospitalizations."
Dirk-Jan Slebos, Ph.D., M.D.
Nuvaira Inc.
3750 Annapolis Lane North
Suite 105
Minneapolis, MN 55447
Main 763.450.2800
info@nuvaira.com
Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD
/in Uncategorized /by eric iversonMinneapolis, Minn., June 27, 2017 – Nuvaira (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient enrollment in the AIRFLOW-2 trial, the first sham-controlled clinical trial of Targeted Lung Denervation* (TLD) using the Nuvaira™ Lung Denervation System in patients with moderate to severe chronic obstructive […]
Holaira Announces Company Name Change to Nuvaira
/in Uncategorized /by eric iversonCompany Adds Shane Gleason to Executive Team Minneapolis, Minn., June 20, 2017 – Holaira, a developer of medical devices to treat obstructive lung diseases, today announced that it has changed its name to Nuvaira, effective immediately. In addition, the company unveiled a new corporate identity and website, available at www.nuvaira.com. The company also announced the […]
Holaira Hosts Educational Symposium on Targeted Lung Denervation (TLD) in Obstructive Lung Disease at ERS
/in Uncategorized /by eric iversonLondon, Sept. 5, 2016 – Holaira, Inc., a developer of medical devices to treat obstructive lung diseases, announced it will host an educational symposium on the use of Targeted Lung Denervation* (TLD) in obstructive lung disease during the European Respiratory Society International Congress, Sept. 6, in London.
First COPD Patient Treated in Holaira’s Sham Controlled Trial of Targeted Lung Denervation
/in Uncategorized /by eric iversonMinneapolis, Minn., Aug. 3, 2016 – Holaira, a developer of medical devices to treat obstructive lung diseases, announced the initiation of treatments in the AIRFLOW-2 Clinical Trial for patients with moderate to severe chronic obstructive pulmonary disease (COPD) in a procedure called Targeted Lung Denervation* (TLD). Under the direction of principal investigator, Christophe Pison, M.D., Ph.D., the first patient was treated at the Grenoble University Hospital Centre (CHUG) in Grenoble, France, using the Holaira™ Lung Denervation System.